文献速递免疫规划卫生政策与健康促进

在南非、越南和澳大利亚社区中三价与四价流感疫苗接种的成本效果

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
PubMed 文献 · Vaccine · 2018-01-17

研究用个体动态模拟模型结合卫生经济学分析,评估2003—2013年南非、越南和澳大利亚社区中15%人口接种四价或三价流感疫苗的成本效果。四价相比三价的增量成本效果比在南非为4183国际美元/质量调整生命年,越南为1505国际美元/质量调整生命年,澳大利亚为80966国际美元/质量调整生命年。四价疫苗的成本效果因社区流感流行病学、合并症和单位成本差异而异。

要点

  • 四价相比三价疫苗的增量成本效果比:南非4183、越南1505、澳大利亚80966国际美元/质量调整生命年。
  • 四价疫苗在南非和越南社区比在澳大利亚带来更大的流感相关发病率下降。
  • 四价与三价疫苗谁最具成本效果,取决于目标接种亚人群的流感B型负担、国家支付意愿阈值和预算影响。

核心结论

  • 四价疫苗的成本效果因社区流感流行病学、合并症和单位成本差异而异。
  • 三价或四价疫苗谁最具成本效果,很大程度上取决于目标接种亚人群的流感B型负担、国家支付意愿阈值和预算影响。

研究设计与样本

  • 个体动态模拟模型与卫生经济学分析模型对接,估计2003—2013年各社区15%人口接种四价或三价流感疫苗的成本效果。
  • 接种优先顺序为HIV感染者,其次为65岁及以上老年人和幼儿。
  • 采用社会视角,结果以每获得一个质量调整生命年的国际美元表示。
  • 流感毒株流行、临床结局和成本数据来自已发表文献的国家或地区特异性资料。

主要发现

  • 与三价疫苗相比,四价疫苗在南非和越南社区比在澳大利亚带来更大的流感相关发病率下降。
  • 四价相比三价的增量成本效果比在南非为4183国际美元/质量调整生命年。
  • 四价相比三价的增量成本效果比在越南为1505国际美元/质量调整生命年。
  • 四价相比三价的增量成本效果比在澳大利亚为80966国际美元/质量调整生命年。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To inform national healthcare authorities whether quadrivalent influenza vaccines (QIVs) provide better value for money than trivalent influenza vaccines (TIVs), we assessed the cost-effectiveness of TIV and QIV in low-and-middle income communities based in South Africa and Vietnam and contrasted these findings with those from a high-income community in Australia. METHODS: Individual based dynamic simulation models were interfaced with a health economic analysis model to estimate the cost-effectiveness of vaccinating 15% of the population with QIV or TIV in each community over the period 2003-2013. Vaccination was prioritized for HIV-infected individuals, before elderly aged 65+ years and young children. Country or region-specific data on influenza-strain circulation, clinical outcomes and costs were obtained from published sources. The societal perspective was used and outcomes were expressed in International$ (I$) per quality-adjusted life-year (QALY) gained. RESULTS: When compared with TIV, we found that QIV would provide a greater reduction in influenza-related morbidity in communities in South Africa and Vietnam as compared with Australia. The incremental cost-effectiveness ratio of QIV versus TIV was estimated at I$4183/QALY in South Africa, I$1505/QALY in Vietnam and I$80,966/QALY in Australia. CONCLUSIONS: The cost-effectiveness of QIV varied between communities due to differences in influenza epidemiology, comorbidities, and unit costs. Whether TIV or QIV is the most cost-effective alternative heavily depends on influenza B burden among subpopulations targeted forvaccination in addition to country-specific willingness-to-pay thresholds and budgetary impact.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. de Boer PT, Kelso JK, Halder N, et al. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. Vaccine. 2018. PMID: 29373192. doi:10.1016/j.vaccine.2017.12.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。